ArticleDiabetology & metabolic syndrome2013
Does Metformin affect ER, PR, IGF-1R, β-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer?
Article in Diabetology & metabolic syndrome, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Metformin and progestins in women with atypical hyperplasia or endometrial cancer: systematic review and meta-analysis.Archives of gynecology and obstetrics · 2024Pooled it
- Metformin Promotes Anti-tumor Biomarkers in Human Endometrial Cancer Cells.Reproductive sciences (Thousand Oaks, Calif.) · 2020Trial
- Women with polycystic ovary syndrome exhibit impaired endometrial receptivity with excessive ERα and histone lactylation.Nature communications · 2026Article
- Investigating the potential role of swertiamarin on insulin resistant and non-insulin resistant granulosa cells of poly cystic ovarian syndrome patients.Journal of ovarian research · 2023Article
- Effect of metformin on proliferative markers in women with endometrial carcinoma: Systematic review and meta-analysis.Turkish journal of obstetrics and gynecology · 2022Article
- Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line.PloS one · 2021Article
- Metformin-activated AMPK regulates β-catenin to reduce cell proliferation in colon carcinoma RKO cells.Oncology letters · 2019Article
- Tropisetron modulates peripheral and central serotonin/insulin levelsRSC advances · 2018Article
- Metformin as a Therapeutic Target in Endometrial Cancers.Frontiers in oncology · 2018Review
- The expression of ER, PR in endometrial cancer and analysis of their correlation with ERK signaling pathway.Cancer biomarkers : section A of Disease markers · 2017Article
- Role of metformin in inhibiting estrogen-induced proliferation and regulating ERα and ERβ expression in human endometrial cancer cells.Oncology letters · 2017Article
- Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients.World journal of gastroenterology · 2017Article
- Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.Oncology reports · 2016Article
- Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.Cancer medicine · 2015Article
- Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.Critical reviews in oncogenesis · 2015Review
- Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma.Journal of experimental & clinical cancer research : CR · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDiabetes mellitus, as a risk factor for endometrial cancer (EC), causes an increase in insulin and IGF-1 concentrations in the blood serum. The increase in insulin and IGF-1 are considered mitogenic factors contributory to cancer development. Studies suggest that metformin has preventive activity, decreasing mortality and the risk of neoplasms. Since estrogen (ER), progesterone (PR) and IGF-1 (IGF-1R) receptor expression and β-catenin and PAX-2 mutations are significant in the development of endometrial cancer, it was decided to study these factors in patients with endometrial cancer and type 2 diabetes mellitus (DM2), and to establish the effects of metformin on their expression.
methodsThe expression of ER, PR, IGF-1R, β-catenin and PAX-2 have been immunohistochemically investigated in 86 type I endometrial cancer specimens. Patients were grouped according to the presence of DM2 and the type of hypoglycemic treatment administered.
resultsComparing EC patients with DM2 and normal glycemic status, we found increased IGF-1R expression in women with DM2. A decrease in ER expression was noted in women with EC and DM2 receiving metformin as compared to women treated with insulin (p = 0.004). There was no statistically significant difference in PR, IGF-1R, β-catenin and PAX-2 expression among women receiving metformin and other hypoglycemic treatment.
conclusionAlthough epidemiological studies suggest the beneficial role of metformin in many human cancers, there are still few studies confirming its favorable effect on endometrial cancer. Decreased ER expression in patients receiving metformin needs further research to allow evaluation of its clinical significance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.